Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Schrodinger Inc (NQ: SDGR )

20.84 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Schrodinger Inc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Schrödinger to Present at Piper Sandler 36th Annual Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger Broadens and Accelerates Predictive Toxicology Initiative
From Schrödinger
Via Business Wire
Earnings Scheduled For November 12, 2024
Via Benzinga
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Schrödinger shares rise as they announce a research partnership and licensing agreement with Novartis AG. Schrödinger will receive $150 million upfront and eligible to receive up to approximately $2.3... 
Via Benzinga
Schrödinger Reports Third Quarter 2024 Financial Results
From Schrödinger
Via Business Wire
Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis
From Schrödinger
Via Business Wire
Schrödinger to Present at Jefferies London Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger to Announce Third Quarter 2024 Financial Results on November 12
From Schrödinger
Via Business Wire
Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual... 
Via Talk Markets
Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug... 
Via Talk Markets
Topics Economy
Exposures Economy
Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week
The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030. 
Via Talk Markets
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD
The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion... 
Via Talk Markets
Schrödinger to Present at Morgan Stanley Global Healthcare Conference
From Schrödinger
Via Business Wire
The 3 Best Med Tech Stocks to Buy Now
Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now. 
Via InvestorPlace
SDGR Stock Earnings: Schrodinger Beats EPS, Beats Revenue for Q2 2024
SDGR stock results show that Schrodinger beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Schrödinger Reports Strong Second Quarter 2024 Financial Results
From Schrödinger
Via Business Wire
AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD
The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030. 
Via Talk Markets
3 Small-Cap Stocks to Buy at a 52-Week Low
The Russell 2000 is hinting at sector rotation, meaning it’s time for bargain hunters to look for small-cap stocks at 52-week lows 
Via InvestorPlace
Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology
From Schrödinger
Via Business Wire
3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts
The Fed is widely expected to cut interest rates a great deal. Here are three stocks to buy to benefit from these interest rate cuts. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD
To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under... 
Via Talk Markets
Schrödinger to Announce Second Quarter 2024 Financial Results on July 31
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.